Rare mesenchymal tumors carrying EWSR1-NFATC2 fusions have been assigned to ESLTs, probably due to partial CD99 expression and/or involvement of the EWSR1 [20–23]. Here, NFATC2 is linked to mesenchymal cell neoplasm.